Datamonitor Healthcare interviewed a US KOL oncologist on HR+ HER2- breast cancer. The topics discussed include clinical and commercial advantages and disadvantages of marketed and late-stage pipeline drugs, pricing, market access and reimbursement issues, and optimum clinical trial design for the indication.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.